Division

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Genezen Announces Strategic Process Development and Manufacturing Partnership Agreement with Seattle Children's Research Institute for X-linked Agammaglobulinemia (XLA) Cell Therapy Program

Retrieved on: 
Wednesday, March 6, 2024

FISHERS, Ind., March 6, 2024 /PRNewswire/ -- Seattle Children's Research Institute, the research division of Seattle Children's Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children's Research Institute's X-linked agammaglobulinemia (XLA) program.

Key Points: 
  • FISHERS, Ind., March 6, 2024 /PRNewswire/ -- Seattle Children's Research Institute, the research division of Seattle Children's Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children's Research Institute's X-linked agammaglobulinemia (XLA) program.
  • This collaborative effort is focused on leveraging Genezen's viral vector process development and cGMP manufacturing expertise to advance Seattle Children's XLA gene therapy program.
  • XLA is a rare primary immunodeficiency condition characterized by abnormally low levels of immunoglobulins, also referred to as antibodies.
  • With this program, Seattle Children's is one of our first customers to leverage our Cytegrity™ producer cell line offering from CSL.

Dr. Honig Joins Legacy as Strategic Advisor, Bringing Expertise in Male Reproductive Health and Urology

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 5, 2024 /PRNewswire/ -- Legacy, the leading provider of at-home sperm testing and freezing solutions in the United States, proudly announces the appointment of Dr. Honig, a distinguished Professor of Urology and Division Chief of Sexual and Reproductive Medicine at Yale University School of Medicine, as a Strategic Advisor.

Key Points: 
  • Dr. Honig's extensive expertise in male reproductive health and urology will significantly enhance Legacy's commitment to innovation in the field of male fertility care.
  • With a remarkable background in academia and clinical practice, Dr. Honig brings a wealth of experience to his new role at Legacy.
  • "The company's commitment to advancing male fertility care aligns with my passion for enhancing access to comprehensive reproductive health services.
  • In his role as a Strategic Advisor, Dr. Honig will provide valuable guidance and strategic vision to further propel Legacy's mission of revolutionizing male fertility care.

Caris Life Sciences Partners with Beat Childhood Cancer Research Consortium at Penn State University to Improve Outcomes for Pediatric Patients

Retrieved on: 
Tuesday, March 5, 2024

IRVING, Texas, March 5, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced an ongoing collaboration with the Beat Childhood Cancer Research Consortium, a group of over 50 universities and children's hospitals, based at Penn State College of Medicine in Hershey, Pa., that offers a worldwide network of pediatric cancer clinical trials.

Key Points: 
  • Caris is now the molecular analysis partner for Beat Childhood Cancer Research Consortium studies.
  • As part of the collaboration to advance precision oncology and biomarker-driven research, Caris is now the molecular analysis partner for Beat Childhood Cancer Research Consortium studies.
  • In addition to tumor sequencing for new or recurring pediatric cancer patients, Caris and the Beat Childhood Cancer Research Consortium will also collaborate on research opportunities striving to advance pediatric patient care and improve outcomes.
  • "The Beat Childhood Cancer Research Consortium is excited to collaborate with Caris to expand our precision medicine program.

Roanoke City Public Schools Partners with Zum to Modernize Student Transportation

Retrieved on: 
Tuesday, March 5, 2024

REDWOOD CITY, Calif., March 5, 2024 /PRNewswire/ -- Roanoke City Public Schools has awarded a $77 million 5-year transportation contract to Zūm, the leader in modern student transportation. 

Key Points: 
  • Virginia Division of 14,000 Students Awards 5-year Contract to Zum for Safe, Reliable Transportation
    REDWOOD CITY, Calif., March 5, 2024 /PRNewswire/ -- Roanoke City Public Schools has awarded a $77 million 5-year transportation contract to Zūm , the leader in modern student transportation.
  • Other districts that have partnered with Zum for school transportation include San Francisco Unified School District, Seattle Public Schools; Howard County Public Schools; Oakland Unified School District; Metro Nashville Public Schools; and Los Angeles Unified School District, the second-largest district in the country.
  • "Student success starts with a safe and reliable ride to school each day," said Dr. Verletta White, Superintendent of Roanoke City Public Schools (RCPS).
  • "We are excited that Roanoke City Public Schools is partnering with Zum for modern student transportation, and we look forward to working with families, drivers and school officials to serve the needs of this vital school community," said Ritu Narayan, Founder and CEO at Zum.

GREENBROOK APPOINTS CHIEF OPERATING OFFICER

Retrieved on: 
Monday, March 4, 2024

TORONTO, March 4, 2024 /PRNewswire/ - Greenbrook TMS Inc. (OTC Pink: GBNHF) ("Greenbrook" or the "Company") announced today the appointment of Andrew Crish as Chief Operating Officer, effective immediately.

Key Points: 
  • TORONTO, March 4, 2024 /PRNewswire/ - Greenbrook TMS Inc. (OTC Pink: GBNHF) ("Greenbrook" or the "Company") announced today the appointment of Andrew Crish as Chief Operating Officer, effective immediately.
  • In his role as Chief Operating Officer, Andrew will have responsibility for Company operations and leading the execution of the Company's strategic growth plan alongside the Company's executive leadership team.
  • Prior to joining Greenbrook, Andrew served as the Vice President of Operations at M2 Orthopedics since December 2021.
  • His passion for driving operational efficiencies and building high-performing teams aligns perfectly with our vision for Greenbrook", commented Bill Leonard, President and Chief Executive Officer.

Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial

Retrieved on: 
Monday, March 4, 2024

SAN DIEGO, March 4, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced new positive long-term AOC 1001 data from the MARINA open-label extension (MARINA-OLE™) trial showing reversal of disease progression in people living with myotonic dystrophy type 1 (DM1) across multiple endpoints including vHOT, muscle strength and activities of daily living when compared to END-DM1 natural history data. These endpoints are the same key endpoints that will be used in the global Phase 3 HARBOR™ trial for people living with DM1. The primary endpoint in the Phase 3 HARBOR trial is video hand opening time (vHOT), and key secondary endpoints include muscle strength as measured by hand grip strength and quantitative muscle testing (QMT) total score, and activities of daily living as measured by DM1-Activ. Avidity is accelerating the global Phase 3 HARBOR trial initiation to the second quarter of 2024.

Key Points: 
  • These endpoints are the same key endpoints that will be used in the global Phase 3 HARBOR™ trial for people living with DM1.
  • Avidity is accelerating the global Phase 3 HARBOR trial initiation to the second quarter of 2024.
  • Avidity also announced delpacibart etedesiran as the approved international nonproprietary name of AOC 1001, abbreviated as del-desiran.
  • ET to discuss new positive long-term del-desiran (AOC 1001) data from the MARINA-OLE™ trial in people living with DM1.

THE CENTER FOR DISCOVERY NAMES DONALD W. LANDRY, MD, PHD AS NEW BOARD MEMBER

Retrieved on: 
Friday, March 1, 2024

HARRIS, N.Y., March 1, 2024 /PRNewswire/ -- The Center for Discovery® (TCFD) today announced that Donald W. Landry, MD, PhD, has been elected to its Board of Directors. His appointment is effective March 1st, 2024.

Key Points: 
  • HARRIS, N.Y., March 1, 2024 /PRNewswire/ -- The Center for Discovery® (TCFD) today announced that Donald W. Landry, MD, PhD, has been elected to its Board of Directors .
  • "Together, our Board of Directors – leaders in their respective industries – provide an invaluable scope of services to The Center.
  • "The vibrant spirit of The Center for Discovery radiates in the persons it serves, its devoted staff and its inspired leadership.
  • I am delighted, and deeply humbled, to join The Board of the Center for Discovery," said Dr. Landry.

American Council of Learned Societies Names Inaugural ACLS HBCU Faculty Fellows and Grantees

Retrieved on: 
Thursday, February 29, 2024

NEW YORK, Feb. 29, 2024 /PRNewswire/ -- The American Council of Learned Societies (ACLS) is pleased to announce the awardees of the new ACLS HBCU Faculty Fellowship and Grant Program. The program provides flexible support that attends to the research, teaching, and service commitments at Historically Black Colleges and Universities (HBCUs). This year, the program will support 20 HBCU faculty scholars pursuing exceptional research projects in the humanities and interpretive social sciences.

Key Points: 
  • NEW YORK, Feb. 29, 2024 /PRNewswire/ -- The American Council of Learned Societies (ACLS) is pleased to announce the awardees of the new ACLS HBCU Faculty Fellowship and Grant Program .
  • The ACLS HBCU Faculty Fellows and Grantees represent 16 HBCUs and a wide range of disciplines and scholarly approaches.
  • "We are thrilled to award these outstanding scholars the inaugural ACLS HBCU Faculty Fellowships and Grants," said ACLS President Joy Connolly.
  • Formed a century ago, the American Council of Learned Societies (ACLS) is a nonprofit federation of 80 scholarly organizations.